• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

119.78 -0.62 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,805,070
Open 122.00
Bid (Size) 119.87 (400)
Ask (Size) 121.00 (200)
Prev. Close 120.40
Today's Range 119.39 - 122.98
52wk Range 88.57 - 128.70
Shares Outstanding 1,253,809,440
Dividend Yield 2.64%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal ↗
Today 12:15 EST
Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial. 
Via Benzinga
News headline image
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains ↗
Today 10:10 EST
Via MarketBeat

Performance

YTD
+30.4%
+30.4%
1 Month
-3.5%
-3.5%
3 Month
+6.4%
+6.4%
6 Month
+8.1%
+8.1%
1 Year
+30.1%
+30.1%

More News

Read More
News headline image
Gilead’s Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Today 8:30 EST
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Why Arcus Biosciences Just Reversed Its 287% Eight-Month Winning Streak ↗
December 12, 2025
Via Investor's Business Daily
News headline image
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era
December 12, 2025
From Equity Insider
Via GlobeNewswire
News headline image
Gilead Sciences Inc. (NASDAQ:GILD) Presents a Compelling Profile for Value Investors ↗
December 12, 2025
Via Chartmill
News headline image
3 Profitable Stocks We Keep Off Our Radar
December 10, 2025
Via StockStory
News headline image
Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer
December 09, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
What Does the Market Think About Gilead Sciences Inc? ↗
December 08, 2025
Via Benzinga
News headline image
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 07, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 06, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 06, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Unpopular Stocks We Think Twice About
December 03, 2025
Via StockStory
News headline image
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
December 03, 2025
Via The Motley Fool
Topics Regulatory Compliance
News headline image
5 Healthcare Names to Watch as Sector Rotation Is in Full Swing ↗
December 01, 2025
Via MarketBeat
News headline image
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today ↗
November 28, 2025
Via Benzinga
News headline image
Top S&P500 movers in Friday's session ↗
November 28, 2025
Via Chartmill
News headline image
These S&P500 stocks are moving in today's session ↗
November 28, 2025
Via Chartmill
News headline image
Gapping S&P500 stocks in Friday's session ↗
November 28, 2025
Via Chartmill
News headline image
Kymera (KYMR) Q3 2025 Earnings Call Transcript ↗
November 27, 2025
Via The Motley Fool
Topics Earnings
News headline image
Gilead Sciences Inc (NASDAQ:GILD) Demonstrates Strong Dividend Reliability and Profitability ↗
November 25, 2025
Via Chartmill
News headline image
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
November 24, 2025
From Gilead Sciences, Inc.
Via Business Wire
News headline image
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today ↗
November 20, 2025
Via Benzinga
News headline image
Gilead Sciences Inc Chart Analysis ↗
November 19, 2025
Via Talk Markets
News headline image
Merck's Investigational Two-Drug Regime Matches Gilead's Three-Drug Tablet For HIV Treatment ↗
November 19, 2025
Via Benzinga

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 119.78
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 12/15/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 150.18B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 150B shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap